Illumina, Inc. · NASDAQ:ILMN

Illumina — Solexa — Merger or Acquisition (November 2006)

41 slides from Illumina's merger presentation, Nov 13, 2006

  1. Slide 1: Jay Flatley, President & CEO

    Jay Flatley President & CEO (c) 2006 Illumina, Inc. Illumina, Sentrix, Array of Arrays, BeadArray, DASL, Infinium, GoldenGate, iSelect, BeadXpress, VeraCode and Making Sense Out of Life are registered trademarks or trademarks of Illumina Inc.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties. Illumina, Inc. ("Illumina") and Solexa, Inc. ("Solexa") caution readers that any forward-looking information is not a guarantee of future performance and actual results could diffe

  3. Slide 3: Our Mission: Provide the Tools that Help Enable Personalized Medicine

    Our Mission: Provide the Tools that Help Enable Personalized Medicine DNA sequence raw data Medically valuable information Personalized Medicine

  4. Slide 4: Large and Rapidly Growing Markets

    Large and Rapidly Growing Markets Research - gold rush to find disease genes associated with complex diseases Whole genome enabled by content and price Expansion into pharma and biotech - improving success rates Monitoring and diagnostic screening 2006 2010 Gene Expression 800 1000 SNP Genotyping 35

  5. Slide 5: Oligator Core Technology

    Oligator(r) Core Technology Proprietary technology to manufacture oligos at high volume and low cost Key raw material for arrays and reagents Enabling for Invitrogen partnership

  6. Slide 6: Illumina's Core BeadArray Technology

    Sentrix(r) Array Matrix Sentrix(r) BeadChip Illumina's Core BeadArrayTM Technology

  7. Slide 7: Broad and Rapidly Growing Application Suite

    ? Custom Assays ? Linkage V4 ? MHC Panel Application Assay/Method Product Configurations Human-1 HumanHap300 HumanHap240s HumanHap550 ? 96 Samples x 1400 Genes ? 16 Samples x 1400 Genes GoldenGate(r) (96, 384, 768, 1536 Multiplex) InfiniumTM (Unlimited Multiplexing) Whole Genome (Direct Hybridizatio

  8. Slide 8: Illumina BeadStation / BeadLab

    Illumina BeadStation / BeadLab

  9. Slide 9: Illumina BeadStation / BeadLab

    Servers Reagents Robots SOPs Illumina BeadStation / BeadLab

  10. Slide 10: Illumina BeadStation / BeadLab

    Illumina BeadStation / BeadLab

  11. Slide 11: Whole Genome Genotyping Infinium Assay

    Whole Genome Genotyping Infinium Assay

  12. Slide 12: Infinium Whole Genome Genotyping Assay Sets Market Standard

    InfiniumTM Whole Genome Genotyping Assay Sets Market Standard for Quality and Performance Robust, single tube assay with no PCR Single chip Full automation support Ability for "intelligent SNP selection" Use of HapMap data HapTag Block Highest information content

  13. Slide 13: Infinium Product Family

    InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306

  14. Slide 14: Infinium Product Family

    InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306

  15. Slide 15: Infinium Product Family

    InfiniumTM Product Family Q206 Q106 Q405 Q305 Q306

  16. Slide 16: HumanHap300-Duo and HumanHap300-Duo+

    HumanHap300-Duo and HumanHap300-Duo+ World's first multi-sample whole genome arrays Based on HumanHap300 content with two samples per chip Streamlines workflow, reduces labor and improves convenience 7th and 8th products launched in Infinium family this year

  17. Slide 17: Recent Deal Summary

    Recent Deal Summary Customer Disease # Samples Product North Shore IBD consortium 2,000 HumanHap300 Genizon 15-20 common 16,000 HumanHap300+ GlaxoSmithKline Not disclosed 2,000 HumanHap550* Mass Gen/Harvard ALS 2,200 HumanHap300 Bovine Consortium Breeding 10,000 iSelect Std. product deCODE Various 1

  18. Slide 18: Erasmus Medical Center

    Erasmus Medical Center Netherlands largest medical facility 10,000 samples using HumanHap550 2 BeadStations Rotterdam Study - a prospectively monitored 17 year cohort Studying late-age diseases including neurological, cardiovascular, endocrine, locomotor and ophthalmological conditions

  19. Slide 19: Large Opportunity in Gene Expression

    Large Opportunity in Gene Expression

  20. Slide 20: Comprehensive Suite of Gene Expression Products

    Comprehensive Suite of Gene Expression Products Screening Toxicology Dx panels Cell cultures Fresh tissue Paraffin Embedded Tissue Biomarkers discovery

  21. Slide 21: Micro Array Quality Control (MAQC) Project

    Micro Array Quality Control (MAQC) Project Goal to generate a set of quality control tools and standards 137 participants 51 organizations (including all commercial expression microarray vendors) FDA, NIH, EPA, USDA www.nature.com/nbt/focus/maqc/index.html Key conclusion: Microarray gene expression

  22. Slide 22: VeraCode: Opening New Markets

    Veracoce| y BY ILLUMINAY Opening New Markets illurnina’ BS SEAS SOE CA EO ENR NT ASE GTS ESE ISSN SRG HNL BCR ES ER NL NN RS ALAA

  23. Slide 23: Clarifying the Nomenclature

    Clarifying the Nomenclature First System Based on VeraCode Technology Digital Microbead Technology CyVera Company Purchased April 2005

  24. Slide 24: Market Needs

    Market Needs Drug efficacy Patient stratifications Clinical trials Disease staging & subtyping Clinical trial patient selection POC Molecular diagnostics R&D Targeted treatment Personalized medicine Theranostics Basic biology of disorders, pathways, hormonal signaling Overall genetic functionality &

  25. Slide 25: Technology / Platform Synergy

    Technology / Platform Synergy Discovery Research Focused Research Molecular Diagnostics WG genotyping WG expression Biomarker discovery Future WG applications Custom genotyping Focused expression DASL Biomarker discovery Low/mid density GT/GEX Protein applications Biomarker screening Biomarker panel

  26. Slide 26: Digital Code Generation

    Digital Code Generation CODE IMAGE 1 0 1 1 0 1 0 1 0 0 0 0 1 0 1 BINARY CODE DECIMAL CODE = 41133 CODE GENERATED BY CREATING EMBEDDED HOLOGRAPHIC DIFFRACTIVE ELEMENTS Glass Surface of Beads Ideal for Bioassays High Density Codes Easily Imprinted (24 bit) Virtually Unlimited Multiplexing CONVENTIONAL

  27. Slide 27: BeadXpress Reader

    BeadXpress Reader INSTRUMENT SPECIFICATIONS SAMPLE DELIVERY FORMAT Standard 96-well plate MULTIPLEXING PER SINGLE WELL 1 to 384 THROUGHPUT 120 samples/hr at 10-plex 80 samples/hr at 96-plex DETECTION Optional 1 or 2 color detection AUTOMATION Designed to be compatible with standard laboratory automa

  28. Slide 28: Eight Wells Read in Parallel

    Eight Wells Read in Parallel EIGHT WELLS ARE SAMPLED SIMULTANEOUSLY AND MICROBEADS ARE TRANSFERRED INTO A MULTI-SECTORED READER CELL.

  29. Slide 29: Beads Align in Groove Plate

    Beads Align in Groove Plate GROOVE PLATE CROSS-SECTION BEADS FALL INTO GROOVE PLATE CAPILLARY FORCE ATTRACTS BEADS INTO GROOVES BEADS ALIGN TIGHTLY FOR OPTIMAL SCANNING EFFICIENCY

  30. Slide 30: Code Detection

    Code Detection BEAD "READING" BEAM CCD LINE ARRAY

  31. Slide 31: Flush Cycle

    Flush Cycle FOLLOWING READOUT, THE BEADS ARE FLUSHED FROM THE READER CELL USING A SECOND ACTUATION PRESSURE CYCLE.

  32. Slide 32: A Flexible Platform for Multiple Applications

    A Flexible Platform for Multiple Applications 100000 10000 1000 100 10 1 0.1 1 10 100 1000 10000 Conc (pM) Counts Analyte Fit 3-sigma LOD GENE EXPRESSION PROTEIN EXPRESSION GENOTYPING

  33. Slide 33: GoldenGate Genotyping Assay

    GoldenGate Genotyping Assay (96 & 384-plex) OPAs + Reagents GoldenGate Genotyping User Manual (RUO) GOLDENGATE GENOTYPING + Beads Pooled in 96-well Plates (96 & 384-plex/well) USER MANUAL IN DEVELOPMENT

  34. Slide 34: Universal Capture Bead Sets

    Universal Capture Bead Sets Unique Bead Code Types in Tubes Assay Design Guidelines (RUO) CUSTOMER DEVELOPED HOMEBREW + GUIDELINES IN DEVELOPMENT Customer controls level of multiplexing and number of samples

  35. Slide 35: Carboxyl Bead Sets (Protein Assays)

    Carboxyl Bead Sets (Protein Assays) Unique Bead Code Types in Tubes Assay Design Guidelines (RUO) CUSTOMER DEVELOPED HOMEBREW + GUIDELINES IN DEVELOPMENT Customer controls level of multiplexing and number of samples

  36. Slide 36: Rollout

    Rollout Q4 Q3 Q3 Q2 Q1 Q4 Q2 Q1 Q4 Q3 Q2 Q1 ISO 13485 Assay/SW Dev - 510K Clinical Trial Commercialization Novel Marker Validation Clinical Trials for PMA(s) System Launch RUO-Home Brew, Novel Marker Discovery, Validation Research Market - Existing Customer Base Field Testing System & Assay Developm

  37. Slide 37: Diagnostic Partnerships

    Diagnostic Partnerships deCODE Myocardial infarction Type II diabetes Breast cancer ReaMetrix Will develop diagnostic assays on BeadXpress ReaMetrix to market in India Illumina has marketing rights outside India Genizon Rights to markers resulting from study of atherosclerosis

  38. Slide 38: Worldwide Sales and Support Network

    Worldwide Sales and Support Network Worldwide Sales and Support Network 33 Direct sales Distributors - Australia/NZ, China, India, Malaysia, South Korea, Taiwan, Thailand, Poland, Spain 58 Technical support

  39. Slide 39: Non-GAAP Q3 Financial Performance

    Revenue $53,472 $ 19,516 $ 73,501 COGS 15,939 6,599 23,181 Gross Margin 37,533 12,917 50,320 % 70.2% 66.2% 68.5% R&D 6,790 7,062 27,725 SG&A 11,734 7,276 27,972 Net Income* 19,917 (1,309) (20,874)** EPS* $0.39 $(0.03) $(0.52)** Non-GAAP Q3 Financial Performance Note: All Numbers in Thousands. (*) Ex

  40. Slide 40: Summary

    Summary Multi-billion dollar opportunity in research and molecular diagnostics markets BeadArray technology is fundamentally flexible, low-cost and scalable Our portfolio of products is growing quickly enabled by a well developed infrastructure and innovative assay technology The VeraCode technology

  41. Slide 41: Slide 41

Solexa — Merger or Acquisition (November 2006) on 6ix